BEAM240920C32000
- 0.55
- 0.000.00%
Beam Therapeutics Newsroom
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Optimistic Outlook on Beam Therapeutics: Advancements and Potential in Precision Genetic Medicines
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine With CRISPR Technology
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases
Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Express News | RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Beam Therapeutics Analyst Ratings
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Express News | Beam Therapeutics Inc : JP Morgan Raises Target Price to $48 From $45
Beam Therapeutics Shares Edge Higher Despite Wider Q2 Loss, Lower Revenue
Beam Therapeutics' Advancements Bolster Buy Rating: Momentum in Gene Editing Trials and Regulatory Progress
Beam Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Beam Therapeutics: U.S. FDA Cleared Investigational New Drug Application for Beam-301 in Glycogen Storage Disease Type Ia
Express News | Beam Therapeutics: Ended Q2 With $1 Bln in Cash, Cash Equivalents & Marketable Securities; Expected Operating Runway Into 2027
Beam Therapeutics 2Q Loss/Shr $1.11 >BEAM